ATE490982T1 - Anti tgr23-2 ligand antikörper und deren verwendungen - Google Patents

Anti tgr23-2 ligand antikörper und deren verwendungen

Info

Publication number
ATE490982T1
ATE490982T1 AT04714918T AT04714918T ATE490982T1 AT E490982 T1 ATE490982 T1 AT E490982T1 AT 04714918 T AT04714918 T AT 04714918T AT 04714918 T AT04714918 T AT 04714918T AT E490982 T1 ATE490982 T1 AT E490982T1
Authority
AT
Austria
Prior art keywords
tgr23
ligand
ligand antibodies
useful
terminal
Prior art date
Application number
AT04714918T
Other languages
English (en)
Inventor
Hirokazu Matsumoto
Eri Hashimoto
Masaaki Mori
Chieko Kitada
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Application granted granted Critical
Publication of ATE490982T1 publication Critical patent/ATE490982T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57535—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the large intestine, e.g. colon, rectum or anus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT04714918T 2003-02-28 2004-02-26 Anti tgr23-2 ligand antikörper und deren verwendungen ATE490982T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003053372 2003-02-28
PCT/JP2004/002293 WO2004076487A1 (ja) 2003-02-28 2004-02-26 抗体およびその用途

Publications (1)

Publication Number Publication Date
ATE490982T1 true ATE490982T1 (de) 2010-12-15

Family

ID=32923430

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04714918T ATE490982T1 (de) 2003-02-28 2004-02-26 Anti tgr23-2 ligand antikörper und deren verwendungen

Country Status (5)

Country Link
US (1) US7342105B2 (de)
EP (1) EP1598369B1 (de)
AT (1) ATE490982T1 (de)
DE (1) DE602004030425D1 (de)
WO (1) WO2004076487A1 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011135904A (ja) * 2008-04-18 2011-07-14 Kowa Co 乳癌及び／又は乳腺炎治療用イオントフォレシス製剤

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010033601A (ko) * 1997-12-24 2001-04-25 다케다 야쿠힌 고교 가부시키가이샤 폴리펩티드, 그의 제법 및 용도
US20030157558A1 (en) * 1999-12-28 2003-08-21 Matsumoto Shun-Ichiro Novel guanosine triphosphate-binding protein-coupled receptors, genes thereof and production and use of the same
JP2001245666A (ja) * 2000-03-06 2001-09-11 Kyowa Hakko Kogyo Co Ltd 新規ポリペプチド
US7250272B2 (en) * 2000-10-13 2007-07-31 Takeda Pharmaceutical Company Limited G protein-coupled receptor protein and DNA thereof
US20030027252A1 (en) 2000-11-22 2003-02-06 Tularik, Inc. Novel receptors
WO2003007187A1 (fr) * 2001-07-12 2003-01-23 Takeda Chemical Industries, Ltd. Procede d'evaluation de ligand et utilisation de ce procede
WO2003025179A1 (fr) * 2001-09-14 2003-03-27 Takeda Chemical Industries, Ltd. Nouveau polypeptide, adn associe et utilisation de ce polypeptide
JP2004275186A (ja) 2003-02-28 2004-10-07 Takeda Chem Ind Ltd 抗体およびその用途

Also Published As

Publication number Publication date
EP1598369B1 (de) 2010-12-08
US20060177449A1 (en) 2006-08-10
US7342105B2 (en) 2008-03-11
DE602004030425D1 (de) 2011-01-20
EP1598369A1 (de) 2005-11-23
EP1598369A4 (de) 2007-05-16
WO2004076487A1 (ja) 2004-09-10

Similar Documents

Publication Publication Date Title
ATE541590T1 (de) Modifizierte antikörper-fragmente
DK1565489T3 (da) Internaliserende antistoffer specifikke for RAAG10-celleoverflademålet
DE602005015542D1 (de) Varianten der fc-region
CY1120640T1 (el) Πεπτιδια σχετιζομενα me tcr-v-bhta για θεραπευτικη αγωγη και διαγνωση αυτοανοσης ασθενειας
CL2007003771A1 (es) Polinucleotido que codifica antigeno de n. meningitidis; vector y celula huesped que lo comprenden; polipeptido codificado; anticuerpo que se une al polipeptido; composicion que comprende el polinucleotido, vector, celula, polipeptido o anticuerpo an
ATE517922T1 (de) Stabilisierte einzel-domänen-antikörper in einer pharmazeutischen zusammensetzung ausgestaltet für inhalation
NZ593289A (en) Anti-neuropilin-1 antibodies for treating angiogenesis
ATE337011T1 (de) Modifizierte psma-liganden und deren verwendung
MA31092B1 (fr) Anticorps humains contre le delta-like ligand 4 humain.
PL2097453T3 (pl) Przeciwciała monoklonalne przeciw ludzkiemu receptorowi hormonu anty-Mullerowskiego typu II (AMHR-II)
WO2004067570A3 (en) Prostate cancer diagnosis and treatment
CY1110759T1 (el) Παραλλαγες ανοσοσφαιρινων και χρησεις αυτων
DK0991421T3 (da) Påvisning og modulering af IAP'er og NAIP i forbindelse med diagnose og behandling af proliferativ sygdom
GEP20115333B (en) Antagonist antibodies directed against calcitonin generelated peptide and using same
CY1110188T1 (el) Αντισωματα κατα συζυγων φωσφορυλχολινης
ATE464374T1 (de) Assay zum schnellen nachweis vom humanen aktivierten protein c und hochspezifischer monoklonaler antikörper dagegen
DK1875237T3 (da) Docetaxel-immunassay
EP2386633A4 (de) Neues tumorantigen eef2
DE60219645D1 (de) Antikörper gegen metastin und dessen verwendung zur diagnose von schwangerschaft
DE602006007967D1 (de) Gegen das gemeinsame epitop von mutierten p53 gerichtete humane synthetische einzelkettenantikörper und anwendungen davon
TW200613734A (en) Detection and identification of peptide and protein modifications
ATE489623T1 (de) Peptide zum nachweis von ehrlichia ewingii antikörper
WO2005041631A3 (en) Endotheliase-1 ligands
BR0113099A (pt) Gene e proteìna relacionados com esquizofrenia
ATE474226T1 (de) Taxol-immunoassay

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties